Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies
Masao Kobayakawa, Yasushi KojimaDepartment of Gastroenterology, National Center for Global Health and Medicine, Tokyo, JapanAbstract: S-1 is a combination of three pharmacological compounds, namely tegafur, gimeracil, and oteracil potassium. Tegafur is a prodrug of 5-fluorouracil (5-FU), an oral flu...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2011-11-01
|
| Series: | OncoTargets and Therapy |
| Online Access: | http://www.dovepress.com/tegafurgimeraciloteracil-s-1-approved-for-the-treatment-of-advanced-ga-a8661 |